Pepperstone logo
Pepperstone logo
  • English
  • عربي
  • Ways to trade

    Pricing

    Trading accounts

    Pro

    Premium clients

    Refer a friend

    Active trader program

    Trading hours

    24-hour trading

    Maintenance schedule

  • Trading platforms

    Trading platforms

    TradingView

    Pepperstone platform

    MetaTrader 5

    MetaTrader 4

    cTrader

    Integrations

    Trading tools

  • Markets

    Markets to trade

    Forex

    Shares

    ETFs

    Indices

    Commodities

    Currency Indices

    Cryptocurrencies

    Dividends for index CFDs

    Dividends for share CFDs

    CFD forwards

  • Market analysis

    Market news

    Navigating Markets

    The Daily Fix

    Meet the analysts

  • Learn to trade

    Trading guides

    CFD trading

    Forex trading

    Commodity trading

    Stock trading

    Crypto trading

    Bitcoin trading

    Technical analysis

    Day trading

    Scalping trading

    Upcoming IPOs

    Gold trading

    Oil trading

    Webinars

  • Professional Clients

  • Partners

  • About us

  • Help and support

  • English
  • عربي
US500

Vaccine trials push through a wave of exuberance

Chris Weston
Chris Weston
Head of Research
9 Nov 2020
Share
The conventional wisdom was that movement was going to come from the US election, not from a vaccine trial update.

However, the Pfizer and BioNtech Phase 3 preliminary trials have caused markets to come alive, not that they needed much encouragement.

While several questions remain unanswered the market has turned to the experts and the reaction from those that know has been quite emphatic. Dr Fauci calling the 90% efficacy rate from the trial “extraordinary’, while most healthcare analysts suggest the results exceeded even the most optimistic market expectations. The vaccine should get FDA approval later this month and the market has treated this news release as a major breakthrough, with calls that at this efficacy rate governments would only need to vaccinate 60% of the country to reach herd immunity.

(Moves on the session)

10_11_2020_DFX1.png

Pfizer has gained 7.7% although well off its highs, but the real winners on the day have been energy and financials, followed with impressive gains in REITS, industrials and materials. Tech has been shunned partly because of the solid gains last week, but because it’s all about value areas of the market with the NAS100 selling accelerating into the close (closing -2.2%). Geographically, European equities have flown with France’s CAC 40 +7.5% and a cure simply can’t come quick enough here, as is the case in the US where case count is exponential and it is going to be a dark winter.

With the roll-out of a vaccine some way off we question if the market is still overlooking the near-term threats? In fact, the Fed mentioned this in its Financial Stability Report (realised in US trade), detailing they see risks that markets take a hit if the virus is not contained in the coming months.

As detailed, value has worked incredibly well with the under-loved sectors of the market playing catch-up, partly helped by US Treasuries getting hammered and with yields on 10 and 30-year Treasuries +11bp and 12bp respectively. Inflation expectations have gained 6bp, so in effect real Treasury yields are up 6bp – not a great breeding ground for gold and silver and when we see the USD up 0.6%, it’s here why we see a sizeable 4.3% move lower in gold and 5.4% in silver.

Consider gold as the anti-bond. If bond yields (especially when we inflation adjust) are moving higher then it subtracts from the attractiveness of yield-less assets and again traders are forced to look elsewhere for returns, especially when the USD is also reacting to moves higher in yield.

The steeper curve trade is back on and that tells a story of an expected recovery – a story we’ve been seeing for a while in industrial metals and cyclical over defensive areas of the stock market. Today we’ve also seen a monster 7.5% rally in crude and that is about pure demand, or at least the perception of it improving. It’s a tough one, as the US winter could see shutdowns as a more defined theme and that will impact demand, but yet as we look into 2021 the idea of a vaccine gives us hope of better times ahead for economics and earnings.

Our XTIUSD market sits with a 40-handle, but the real test comes in moves into $41.59 and there will be a few traders lining up to fade rallies into here.

10_11_2020_DFX2.png

The move in Treasuries means buying value over growth and small caps over large. The long Russell 2000 and short NAS100 has worked well and if we want to express a cyclical recovery this is a trade to watch. In FX markets the moves in US bond yields have resonated in USDJPY and USDCNH moving higher. We’ve also seen EURUSD moving from 1.1920 into 1.1800 before buyers have supported and with it, interest rate markets have started to warm up a little here which is being seen as a USD positive.

10_11_2020_DFX3.png

Here we see the Eurodollar interest markets. By looking at difference in the yield on the December 2020 contract versus future contracts (I’ve looked at Dec 2022, 2023, 2024 and 2025), we can see the number of basis points of hikes priced for that period. Rates markets are on the move, but with just 14bp of hikes priced by end-2022 its hardly panic stations. However, if the market continues to look past COVID-19 issues and what 2021 could look like, the USD will turn from a sentiment vehicle to one that reassembles a cyclical currency again - even if the Fed will tolerate inflation under its new regime. This will support USDJPY and USDCHF above others.


Related articles

Will the long equity short USD trade spill into this week?

Will the long equity short USD trade spill into this week?

USD
Which way for Oil?

Which way for Oil?

Oil

Most read

1

The disinflationary message seen in commodities and rates markets

2

Will the BOJ be the last dovish domino to fall?

3

Trader thoughts - the conflicting forces dictating EURUSD flow

Ready to trade?

It's quick and easy to get started. Apply in minutes with our simple application process.

Get startedSubscribe to The Daily Fix

The material provided here has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Whilst it is not subject to any prohibition on dealing ahead of the dissemination of investment research we will not seek to take any advantage before providing it to our clients.

Pepperstone doesn’t represent that the material provided here is accurate, current or complete, and therefore shouldn’t be relied upon as such. The information, whether from a third party or not, isn’t to be considered as a recommendation; or an offer to buy or sell; or the solicitation of an offer to buy or sell any security, financial product or instrument; or to participate in any particular trading strategy. It does not take into account readers’ financial situation or investment objectives. We advise any readers of this content to seek their own advice. Without the approval of Pepperstone, reproduction or redistribution of this information isn’t permitted.

Other sites

  • The Trade Off
  • Partners
  • Group
  • Careers

Ways to trade

  • Pricing
  • Trading accounts
  • Pro
  • Premium clients
  • Active trader program
  • Refer a friend
  • Trading hours

Platforms

  • Trading platforms
  • Trading tools

Markets and Symbols

  • Forex
  • Shares
  • ETFs
  • Indicies
  • Commodities
  • Currency indicies
  • Cryptocurrencies
  • CFD forwards

Analysis

  • Navigating Markets
  • The Daily Fix
  • Pepperstone Pulse
  • Meet the Analysts

Learn to trade

  • Trading Guides
  • Videos
  • Webinars
Pepperstone logo
support.ae@pepperstone.com
+97145734100
Al Fattan Currency House
Level 15, Office 1502 A, Tower 2
P.O.Box 482087, DIFC
Dubai, United Arab Emirates
  • Legal documents
  • Privacy policy
  • Website terms and conditions
  • Cookie policy
  • Whistleblower policy

© 2025 Pepperstone Financial Services (DIFC) Limited

Risk warning: Trading CFDs and FX carries significant risk. Trading OTC derivatives may not be suitable for everyone so please ensure that you fully understand the risks involved and take care to manage your exposure. You have no ownership of the underlying asset. Pepperstone Financial Services (DIFC) Limited does not issue advice, recommendations or opinion in relation to acquiring, holding or disposing of OTC derivatives nor is Pepperstone a financial advisor. All services are provided on an execution only basis. Pepperstone Financial Services (DIFC) Limited only provides information of a general nature and does not take into account your financial objectives, personal circumstances. We recommend that you seek independent personal financial or legal advice.

Pepperstone Financial Services (DIFC) Limited is registered at Al Fattan Currency House, Tower 2, Level 15, Office 1502 A, P. O. Box 482087, DIFC, Dubai, United Arab Emirates and is regulated by the DFSA under license number F004356.

The product issuer is Pepperstone Group Limited registered at Level 16, Tower One, 727 Collins St, Docklands, Victoria 3008, Australia and is licensed and regulated by the Australian Securities and Investments Commission, AFSL 414530. You should consider whether you are part of the product issuer’s target market by reviewing the TMD, and read the PDS and other legal documents to ensure you fully understand the risks before you make any trading decisions.